ACH-OLMESARTAN TABLET

দেশ: কানাডা

ভাষা: ইংরেজি

সূত্র: Health Canada

সক্রিয় উপাদান:

OLMESARTAN MEDOXOMIL

থেকে পাওয়া:

ACCORD HEALTHCARE INC

এটিসি কোড:

C09CA08

INN (আন্তর্জাতিক নাম):

OLMESARTAN MEDOXOMIL

ডোজ:

40MG

ফার্মাসিউটিকাল ফর্ম:

TABLET

রচনা:

OLMESARTAN MEDOXOMIL 40MG

প্রশাসন রুট:

ORAL

প্যাকেজ ইউনিট:

30/90/100/500/1000

প্রেসক্রিপশন টাইপ:

Prescription

থেরাপিউটিক এলাকা:

ANGIOTENSIN II RECEPTOR ANTAGONISTS

পণ্য সারাংশ:

Active ingredient group (AIG) number: 0152496003; AHFS:

অনুমোদন অবস্থা:

APPROVED

অনুমোদন তারিখ:

2017-05-01

পণ্য বৈশিষ্ট্য

_ACH-Olmesartan_
_Page 1 of 28 _
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
ACH-OLMESARTAN
Olmesartan Medoxomil Tablets
20 mg and 40 mg, Oral
USP
Angiotensin II AT
1
Receptor Blocker
Accord Healthcare Inc.
3535 boul. St. Charles suite 704
Kirkland, QC, H9H 5B9
Canada
Date of Initial Authorization:
May 1, 2017
Date of Revision:
October 6, 2021
Submission Control No: 252305
_ACH-Olmesartan_
_Page 2 of 28 _
RECENT MAJOR LABEL CHANGES
2 CONTRAINDICATIONS, Pregnancy and
Breastfeeding
10/2021
7 Warnings and Precautions, 7.1 Special
Populations, 7.1.1 Pregnant women
10/2021
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.......................................................................4
1
INDICATIONS
................................................................................................................4
1.1
Pediatrics
............................................................................................................4
1.2
Geriatrics.............................................................................................................4
2
CONTRAINDICATIONS
...................................................................................................4
3
SERIOUS WARNINGS AND PRECAUTIONS BOX
..............................................................5
4
DOSAGE AND
ADMINISTRATION...................................................................................5
4.1
Dosing Considerations
.........................................................................................5
4.2
Recommended Dose and Dosage
Adjustment.......................................................6
4.3
Reconstitution
.....................................................................................................6
4.4
Administration.....................................................................................................6
4.5
Missed Dose
........................................................................................................7
5
OVERDOSAGE
................